Phase I and II agents in cancer therapy: two cisplatin analogues and high-dose cisplatin in hypertonic saline or with thiosulfate protection

Journal of Clinical Pharmacology
J Z FuksP H Wiernik

Abstract

Cisplatin is a chemotherapeutic coordination complex that has been evaluated extensively. It is particularly active against testicular cancer, but carcinomas of the ovary, bladder, cervix, and head and neck are also responsive. To increase efficacy and decrease toxicity, a number of platinum analogues have been developed and tested. One of these, carboplatin, is of particular interest. In clinical trials, it has demonstrated antitumor activity comparable to that of cisplatin, without evidence of significant renal toxicity or neurotoxicity. A second interesting platinum analogue is iproplatin. Preliminary phase I studies suggest reduced adverse renal and neurologic effects similar to those seen with carboplatin, with efficacy comparable to cisplatin. Attempts to overcome the dose-limiting toxicity of cisplatin by administering high-dose cisplatin (40 mg/m2/d for five days) in hypertonic saline or with thiosulfate protection are also reviewed. These techniques have eliminated nephrotoxicity as the dose-limiting toxicity of cisplatin. However, nonrenal toxicity, especially neurotoxicity, remains substantial. The extent to which high-dose cisplatin-based chemotherapy should be used in routine clinical practice has not been determined.

References

Feb 8, 1979·The New England Journal of Medicine·L H Einhorn, S D Williams
Sep 1, 1985·Cancer Treatment Reviews·J G McVieI Klein
Sep 1, 1985·Cancer Treatment Reviews·E Wiltshaw
Feb 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C E PfeifleM P Murphy
Jan 1, 1984·Annals of Internal Medicine·R F OzolsR C Young
May 1, 1984·Annals of Internal Medicine·P J Loehrer, L H Einhorn
Dec 1, 1982·Annals of Internal Medicine·S B HowellM Green
Aug 1, 1982·Journal of Medicinal Chemistry·D B BrownD Frost
Aug 1, 1981·Gynecologic Oncology·H W BrucknerJ F Holland

❮ Previous
Next ❯

Citations

May 15, 1991·Biochemical Pharmacology·G S BaldewN P Vermeulen
Jul 22, 1992·Biochemical Pharmacology·G S BaldewN P Vermeulen
Aug 28, 2009·European Journal of Cancer Care·A P GreystokeM J Mackean
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F P HarmersJ P Neijt
Jun 13, 2017·Chemical Reviews·Fan HongHao Yan
Nov 10, 2018·ACS Omega·Eva Villar-AlvarezVíctor Mosquera
Jul 19, 2012·Journal of the American Chemical Society·Qiao JiangBaoquan Ding

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.